Session 35 - 12th CROI

Home

Session 35 Oral Abstracts
Infectious Complications: Prevention and Treatment
Friday, 10 am - 12:30 pm
Ballroom A

10:30 am 138	Acute Invasive Bacterial Infections and the Natural History of HIV-1 Disease in Uganda Edward N Janoff*, C Gilks, D Nelson, J Nakiyingi, L Awoyinka, E Lugada, J Whitworth, H Rubins, and N French Univ of Minnesota, Minneapolis, USA
10:45 am 139	The Incidence of Invasive Pneumococcal Disease in the Era of HAART Is the Same as that in the Pre-HAART Era Gregory Lucas*, J Keruly, K Gebo, and R Moore Johns Hopkins Univ Sch of Med, Baltimore, MD, USA
11:00 am 140	Immunologic Efficacy of a Prime-boost Strategy Combining a 7-Valent Pneumococcal Conjugate Vaccine followed by a 23-Valent Pneumococcal Polysaccharide Vaccine vs PPV Alone in HIV-infected Adults with 200 to 500 CD4 Cells/mL. Results of the ANRS 114 Study Philippe Lesprit*¹, G Pedrono², J M Molina³, C Goujard⁴, P M Girard⁵, N Sarrazin², C Katlama⁶, P Yéni⁷, P Morineau⁸, B Fritzell⁹, J F Delfraissy⁴, G Chène², Y Lévy¹, and A Study Group¹⁰ ¹Henri Mondor Hosp, Créteil, France; ²INSERM U330, Bordeaux, France; ³Hosp St-Louis, Paris, France; ⁴Kremlin-Bicetre Hosp, France; ⁵Hosp St-Antoine, Paris, France; ⁶La Pitié Hosp, Paris, France; ⁷Hosp Bichat-Claude Bernard, Paris, France; ⁸Hôtel Dieu Hosp, Nantes, France; ⁹Wyeth Lederle, Paris, France; and ¹⁰French Natl Agency for AIDS Res, Paris, France
11:15 am 141	Randomized Clinical Trial of 6-month versus 9-month Anti-Tuberculosis Treatment in HIV+ Individuals with Pulmonary Tuberculosis Soumya Swaminathan*¹, S Iliayas¹, C Padmapriyadarsini¹, S Rajasekaran², V Mohan¹, C Ponnuraja¹, P Venkatesan¹, R Ramachandran¹, C Paramasivan¹, S Ramesh Kumar¹, P Menon¹, M Dilip¹, and P Narayanan¹ ¹Tuberculosis Res Ctr, Chennai, India and ²Govt Hosp of Thoracic Med, Chennai, India
11:30 am 142	Incidence of and Risk Factors for Clinically Significant MRSA Infection in a Cohort of HIV-infected Adults: Relation to Severity of HIV Disease Christopher Mathews*¹, F Torriani¹, L Miller², E Barber¹, J Caperna¹, S May¹, and A McCutchan¹ ¹Univ of California, San Diego, USA and ²Univ of California, Los Angeles, USA
11:45 am 143LB	2 Million Years of Life Saved: The Survival Benefits of AIDS Therapy in the United States Rochelle P. Walensky*^1,2, A Paltiel³, E Losina⁴, L Mercincavage⁴, B Schackman⁵, P Sax², M Weinstein⁶, and K Freedberg⁶ ¹Harvard Med Sch, Boston, MA, USA; ²Brigham and Women's Hospital, Boston, MA, USA; ³Yale School of Medicine, New Haven, CT, USA; ⁴Boston Univ, MA, USA; ⁵Weill Med Coll, Cornell Univ, New York, NY, USA; and ⁶Harvard Sch of Publ Hlth, Boston, MA, USA